127 related articles for article (PubMed ID: 37962373)
1. Discovery of potential RIPK1 inhibitors by machine learning and molecular dynamics simulations.
Liu JX; Na RS; Yang LJ; Huang XR; Zhao X
Phys Chem Chem Phys; 2023 Nov; 25(45):31418-31430. PubMed ID: 37962373
[TBL] [Abstract][Full Text] [Related]
2. Discovering the Active Ingredients of Medicine and Food Homologous Substances for Inhibiting the Cyclooxygenase-2 Metabolic Pathway by Machine Learning Algorithms.
Tian Y; Zhang Z; Yan A
Molecules; 2023 Sep; 28(19):. PubMed ID: 37836625
[TBL] [Abstract][Full Text] [Related]
3. Checking the STEP-Associated Trafficking and Internalization of Glutamate Receptors for Reduced Cognitive Deficits: A Machine Learning Approach-Based Cheminformatics Study and Its Application for Drug Repurposing.
Jamal S; Goyal S; Shanker A; Grover A
PLoS One; 2015; 10(6):e0129370. PubMed ID: 26066505
[TBL] [Abstract][Full Text] [Related]
4. The use of machine learning modeling, virtual screening, molecular docking, and molecular dynamics simulations to identify potential VEGFR2 kinase inhibitors.
Salimi A; Lim JH; Jang JH; Lee JY
Sci Rep; 2022 Nov; 12(1):18825. PubMed ID: 36335233
[TBL] [Abstract][Full Text] [Related]
5. Harnessing Protein-Ligand Interaction Fingerprints to Predict New Scaffolds of RIPK1 Inhibitors.
Aniceto N; Marques V; Amaral JD; Serra PA; Moreira R; Rodrigues CMP; Guedes RC
Molecules; 2022 Jul; 27(15):. PubMed ID: 35897894
[TBL] [Abstract][Full Text] [Related]
6. Shape-based Machine Learning Models for the Potential Novel COVID-19 Protease Inhibitors Assisted by Molecular Dynamics Simulation.
Nayarisseri A; Khandelwal R; Madhavi M; Selvaraj C; Panwar U; Sharma K; Hussain T; Singh SK
Curr Top Med Chem; 2020; 20(24):2146-2167. PubMed ID: 32621718
[TBL] [Abstract][Full Text] [Related]
7. Machine Learning-Based Drug Repositioning of Novel Janus Kinase 2 Inhibitors Utilizing Molecular Docking and Molecular Dynamic Simulation.
Yasir M; Park J; Han ET; Park WS; Han JH; Kwon YS; Lee HJ; Chun W
J Chem Inf Model; 2023 Nov; 63(21):6487-6500. PubMed ID: 37906702
[TBL] [Abstract][Full Text] [Related]
8. Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis.
Le Cann F; Delehouzé C; Leverrier-Penna S; Filliol A; Comte A; Delalande O; Desban N; Baratte B; Gallais I; Piquet-Pellorce C; Faurez F; Bonnet M; Mettey Y; Goekjian P; Samson M; Vandenabeele P; Bach S; Dimanche-Boitrel MT
FEBS J; 2017 Sep; 284(18):3050-3068. PubMed ID: 28715128
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel JAK1 inhibitors through combining machine learning, structure-based pharmacophore modeling and bio-evaluation.
Wang Z; Sun L; Xu Y; Liang P; Xu K; Huang J
J Transl Med; 2023 Aug; 21(1):579. PubMed ID: 37641144
[TBL] [Abstract][Full Text] [Related]
10. RIPK1 inhibitor Cpd-71 attenuates renal dysfunction in cisplatin-treated mice via attenuating necroptosis, inflammation and oxidative stress.
Wang JN; Liu MM; Wang F; Wei B; Yang Q; Cai YT; Chen X; Liu XQ; Jiang L; Li C; Hu XW; Yu JT; Ma TT; Jin J; Wu YG; Li J; Meng XM
Clin Sci (Lond); 2019 Jul; 133(14):1609-1627. PubMed ID: 31315969
[TBL] [Abstract][Full Text] [Related]
11. Machine Learning-Based Virtual Screening for the Identification of Cdk5 Inhibitors.
Di Stefano M; Galati S; Ortore G; Caligiuri I; Rizzolio F; Ceni C; Bertini S; Bononi G; Granchi C; Macchia M; Poli G; Tuccinardi T
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142566
[TBL] [Abstract][Full Text] [Related]
12. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target.
Mifflin L; Ofengeim D; Yuan J
Nat Rev Drug Discov; 2020 Aug; 19(8):553-571. PubMed ID: 32669658
[TBL] [Abstract][Full Text] [Related]
13. Engineering novel scaffolds for specific HDAC11 inhibitors against metabolic diseases exploiting deep learning, virtual screening, and molecular dynamics simulations.
Li J; Chen X; Liu R; Liu X; Shu M
Int J Biol Macromol; 2024 Mar; 262(Pt 2):129810. PubMed ID: 38340912
[TBL] [Abstract][Full Text] [Related]
14. Machine Learning, Molecular Docking, and Dynamics-Based Computational Identification of Potential Inhibitors against Lung Cancer.
Das AP; Mathur P; Agarwal SM
ACS Omega; 2024 Jan; 9(4):4528-4539. PubMed ID: 38313551
[TBL] [Abstract][Full Text] [Related]
15. Exploring Antiviral Drugs on Monolayer Black Phosphorene: Atomistic Theory and Explainable Machine Learning-Assisted Platform.
Laref S; Harrou F; Sun Y; Gao X; Gojobori T
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732115
[TBL] [Abstract][Full Text] [Related]
16. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.
Najjar M; Suebsuwong C; Ray SS; Thapa RJ; Maki JL; Nogusa S; Shah S; Saleh D; Gough PJ; Bertin J; Yuan J; Balachandran S; Cuny GD; Degterev A
Cell Rep; 2015 Mar; 10(11):1850-60. PubMed ID: 25801024
[TBL] [Abstract][Full Text] [Related]
17. Molecular modeling provides a structural basis for PERK inhibitor selectivity towards RIPK1.
Chintha C; Carlesso A; Gorman AM; Samali A; Eriksson LA
RSC Adv; 2019 Dec; 10(1):367-375. PubMed ID: 35558862
[TBL] [Abstract][Full Text] [Related]
18. Machine learning algorithms identify hypokalaemia risk in people with hypertension in the United States National Health and Nutrition Examination Survey 1999-2018.
Lin Z; Cheng YT; Cheung BMY
Ann Med; 2023 Dec; 55(1):2209336. PubMed ID: 37162442
[TBL] [Abstract][Full Text] [Related]
19. Design of Novel IRAK4 Inhibitors Using Molecular Docking, Dynamics Simulation and 3D-QSAR Studies.
Bhujbal SP; He W; Hah JM
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234844
[TBL] [Abstract][Full Text] [Related]
20. Fast and accurate prediction of partial charges using Atom-Path-Descriptor-based machine learning.
Wang J; Cao D; Tang C; Chen X; Sun H; Hou T
Bioinformatics; 2020 Sep; 36(18):4721-4728. PubMed ID: 32525553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
